Gabriele Edoardo Braglia

Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ.

Kyowa Kirin International Plc is a specialty pharmaceutical company, which engages in the development and commercialization of prescription medicines for the treatment of unmet therapeutic needs in major markets. It offers Sancuso, a prescription medicine used to prevent nausea and vomiting in people receiving some types of chemotherapy treatment and Abstral, a medicine used in the management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. The company was founded in 1995 and is headquartered in Galashiels, the United Kingdom.

New York Philharmonic provides live theatrical presentations. The company was founded in 1842 and is headquartered in New York, NY.

Part of Eisai Co., Ltd., Eisai Corp. of North America is a pharmaceutical company that manufactures pharmaceutical products. The company is based in Woodcliff Lake, NJ.

The European Federation of Pharmaceutical Industries & Assns is a trade association that promotes pharmaceutical discovery and development. The non-profit company is based in Brussels, Belgium.

Part of Biogen, Inc., Biogen Idec, Inc. (North Carolina) is a pharmaceutical company based in Durham, NC. The company develops pharmaceutical products. Michel Pericles Vounatsos has been the CEO of the company since 2016.

MGI PHARMA Biologics, Inc. develops and markets pharmaceutical and medical therapies. The company's products amolimogene and ZYC300 represent a breakthrough in the activition of cytotoxic cells. The company was founded in 1979 and is located in Lexington, MA

Italfarmaco SpA engages in the production and distribution of pharmaceutical and fine chemical products. It also provides research and development, scientific publishing, business development, and licensing services. The company was founded in 1938 and is headquartered in Milan, Italy.

Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland.

Helsinn Therapeutics (U.S.), Inc. develops, manufactures and supplies pharmaceutical products for treatment of cancer. The company is headquartered in Iselin. NJ.

Quanta Dialysis Technologies Ltd. develops haemodialysis systems. The firm's SC+ is a performance, portable, compact haemodialysis system providing clinical efficacy utilising flow rates typically used on traditional machines. It offers SelfCare+, a haemodialysis machine for dialysis patients to control their disease and determine the treatment regime and care. The company was founded by Clive Henrey Buckberry, John Eric Milad and Martin Johnson in 2008 and is headquartered in Alcester, the United Kingdom.

BSP Pharmaceuticals SpA develops and manufactures anticancer drugs. It offers development, clinical supply, commercial supply, and analytical services. The company was founded by Aldo Braca in July 2006 and is headquartered in Latina Scalo, Italy.

Helsinn Birex Pharmaceuticals Ltd. develops and manufactures oral dosage drug products. It is engaged in providing oral solid dosage forms and topical forms of pharmaceutical products and packaging of sterile products. The firm supplies its partners with ready to sell products on an exclusive basis, which are manufactured on site and using a network of external manufacturing partners. The company was founded by Gabriele Braglia on May 18, 1978 and is headquartered in Dublin, Ireland.

Prismic Pharmaceuticals, Inc. engages in the research and development of prescription drugs for kidney disease, mental health, and chronic pain. It also offers medical foods for patients with chronic kidney disease, and depression and bipolar disorder. The company was founded by Zachary Dutton, Danilo Casadei Massari, and Peter J. Moriarty in 2011 and is headquartered in Worcester, MA.

Cell Therapy Ltd. produces regenerative medicines using adult stem cells to treat heart failure. Its product HeartCel, a stem cell therapy that offers improved outcomes for heart failure patients by reducing the size of heart scar, improving heart function, quality of life and reducing mortality. The firm develops therapies based on the adult mesenchymal stromal cells technology platform. The firm’s regenerative therapies will focus on curing the cause of the disease, rather than only treating the symptoms. The company was founded in 2009 by Martin John Evans and Ajan Trevor Reginald and is headquartered in Cardiff, the United Kingdom.

3B FUTURE HEALTH VENTURES SARL (3B Future Health Ventures) is a venture capital subsidiary of Helsinn Healthcare SA founded in 2016. The firm is headquartered in Monaco, Luxembourg.

Greenbone Ortho SRL develops a wood-derived bone implants technology to generate biomimetic implant suitable to address non-union fractures. It offers GreenBone that reproduce chemical composition and thee-dimensional architecture of natural tissues. The company was founded by Lorenzo Pradella in 2014 and is headquartered in Faenza, Italy.

FSI SGR SpA (FSI) also known as Fondo Strategico Italiano, is an independent private equity firm. The firm was founded in 2016 and is headquartered in Milan, Italy.

QuantuMDx Group Ltd. develops devices for diagnostics detection. The firm offers DNA-XT, Under The Tree Diagnostics, Q-POC, and Internet of Life. The company was founded by Jonathan O'Halloran, Elaine Warburton, and Julian Warburton in March 2008 and is headquartered in Newcastle upon Tyne, the United Kingdom.

Micromega Ltd. provides business support services. The private company is based in London, UK. The British company was founded by Francesco Granata.

Utility Therapeutics Ltd. is a British company that has exclusive US commercial rights to two European-approved antibiotics, mecillinam and an oral prodrug of mecillinam, for the treatment of urinary tract infections (UTI). The private company is based in Altrincham, UK and was founded in 2018 by Rasmus Toft-Kehler, Morten Otto Alexander Sommer, Peter Aksel Villadsen. Mecillinam is being developed as a first-line therapy for complicated UTI in the hospital setting, while the oral prodrug is being developed for uncomplicated UTI. The company has received the FDA's Qualified Infectious Disease Product (QIDP) designation for the treatment of UTI. Utility Therapeutics is committed to developing antibiotics that meet urgent treatment needs for multi-drug resistant infections.

Diadem Srl predicts, monitors, diagnosis and drug development for Alzheimer?s disease. focuses on specific research on early peripheral markers of Alzheimer's disease into technology. The company was founded by Maurizio Memo and Daniela Uberti in June 2012 and is headquartered in Brescia, Italy.

GT Gain Therapeutics SA operates as a preclinical stage biotech firm developing a class of next generation brain-penetrant non-competitive pharmacological chaperones for the treatment of devastating diseases using the proprietary SEE-Tx technology. Its projects include Beta-galactosidase GLB1 gene and Glucosylceramidase GBA gene. The company was founded by Lorenzo Leoni and is headquartered in Lugano, Switzerland.

3B Future Health Fund II S.C. A. SICAV-RAIF invests in companies located in the US, Europe, Israel and Japan. The fund target companies operating in the fields of healthcare. It provides financing for early stage capital requirements with an investment up to USD 12 million. It also makes follow on investment and take a seat on the board of director.